A review of patents relating to therapeutic angiogenesis using endothelial progenitors and other vasculogenesis-related cell types

Recent Patents on Regenerative Medicine

Volumn 3, Issue 1, 2013, Pages 63-73

  Medina, Reinhold J ^a   O'Neill, Christina L ^a   O'Doherty, Teresa M ^a   Wilson, Sarah E J ^a   Stitt, Alan W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Angiogenesis; Bone marrow; Endothelial progenitor; Monocyte; Stem cell; Vascular repair; Vasculogenesis

Indexed keywords

ANGIOPOIETIN RECEPTOR; BLOOD CLOTTING FACTOR 8; CD133 ANTIGEN; CD135 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; ENDOGLIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KRUPPEL LIKE FACTOR 4; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT INTERLEUKIN 6; RECOMBINANT STEM CELL FACTOR; RECOMBINANT VASCULOTROPIN; THY 1 ANTIGEN; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; ENDOTHELIAL PROGENITOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIA; MONOCYTE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RETINOPATHY; SKIN ULCER;

EID: 84876510198     PISSN: 22102965     EISSN: 22102973     Source Type: Journal    
DOI: 10.2174/2210296511303010063     Document Type: Article

References (100)

1. Power C, Rasko JE. Promises and challenges of stem cell research for regenerative medicine. Ann Intern Med 2011; 155: 706-13.
2. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplanta-tion for organ vascularization and regeneration. Nat Med 2003; 9: 702-12.
3. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004; 255: 538-61.
4. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 2002; 105: 788-93.
5. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-7.
6. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Gior-dano FJ, et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107: 1359-65.
7. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733-42.
8. Yang Z, von Ballmoos MW, Faessler D, Voelzmann J, Ortmann J, Diehm N, et al. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothe-lial cells. Atherosclerosis 2010; 211: 103-9.
9. Le Blanc K. Immunomodulatory effects of fetal and adult mesen-chymal stem cells. Cytotherapy 2003; 5: 485-9.
10. Cao JP, He XY, Xu HT, Zou Z, Shi XY. Autologous transplanta-tion of peripheral blood-derived circulating endothelial progenitor cells attenuates endotoxin-induced acute lung injury in rabbits by direct endothelial repair and indirect immunomodulation. Anesthe-siology 2012; 116: 1278-87.
11. Di Santo S, Yang Z, Wyler von Ballmoos M, Voelzmann J, Diehm N, Baumgartner I, et al. Novel cell-free strategy for therapeutic an-giogenesis: In vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 2009; 4: e5643.
12. Tateno K, Minamino T, Toko H, Akazawa H, Shimizu N, Takeda S, et al. Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization. Circ Res 2006; 98: 1194-202.
13. Yasuda K, Khandare A, Burianovskyy L, Maruyama S, Zhang F, Nasjletti A, et al. Tunneling nanotubes mediate rescue of prema-turely senescent endothelial cells by endothelial progenitors: Ex-change of lysosomal pool. Aging 2011; 3: 597-608.
14. Beeres SL, Atsma DE, van Ramshorst J, Schalij MJ, Bax JJ. Cell therapy for ischaemic heart disease. Heart 2008; 94: 1214-26.
15. Sekiguchi H, Ii M, Losordo DW. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J Cell Physiol 2009; 219: 235-42.
16. Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schachinger V, Lehmann R, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): Final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 2011; 100: 925-34.
17. Hansson EM, Lindsay ME, Chien KR. Regeneration next: Toward heart stem cell therapeutics. Cell Stem Cell 2009; 5: 364-77.
18. Lasala GP, Silva JA, Gardner PA, Minguell JJ. Combination stem cell therapy for the treatment of severe limb ischemia: Safety and efficacy analysis. Angiology 2010; 61: 551-6.
19. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002; 360: 427-35.
20. Kajiguchi M, Kondo T, Izawa H, Kobayashi M, Yamamoto K, Shintani S, et al. Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circ J 2007; 71: 196-201.
21. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209: 10-7.
22. Kornowski, R., Fuchs, S., Epstein, S.E., Leon, M.B. Intramyocar-dial injection of autologous bone marrow. US7097832 (2006).
23. Wara AK, Croce K, Foo S, Sun X, Icli B, Tesmenitsky Y, et al. Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells: Implications for ischemic cardiovascular dis-ease. Blood 2011; 118: 6461-4.
24. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circu-lation 2010; 121: 2437-45.
25. Okuno Y, Nakamura-Ishizu A, Kishi K, Suda T, Kubota Y. Bone marrow-derived cells serve as proangiogenic macrophages but not endothelial cells in wound healing. Blood 2011; 117: 5264-72.
26. Ishikawa K, Yoshida S, Nakao S, Sassa Y, Asato R, Kohno R, et al. Bone marrow-derived monocyte lineage cells recruited by MIP-1beta promote physiological revascularization in mouse model of oxygen-induced retinopathy. Lab Invest 2012; 92: 91-101.
27. Wagner EM, Sanchez J, McClintock JY, Jenkins J, Moldobaeva A. Inflammation and ischemia-induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L351-7.
28. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Mono-cyte/macrophage infiltration in tumors: Modulators of angiogene-sis. J Leukoc Biol 2006, 80:1183-1196.
29. Pawliuk, R., Leboulch, P. Methods and compositions for promoting angiogenesis using monocytes. US20020034501 (2002).
30. Naldini, L., De Palma, M., Venneri, M.A.L. Monocyte cell. US7833789 (2010).
31. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic TIE2-expressing mono-cytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-85.
32. Sanberg, P.R., Hossne, N.A., Willing, A.E., Invitti, A. Ischemic tissue cell therapy. US20110274674 (2011).
33. Sanberg PR, Park DH, Kuzmin-Nichols N, Cruz E, Hossne NA, Jr., Buffolo E, et al. Monocyte transplantation for neural and cardio-vascular ischemia repair. J Cell Mol Med 2010; 14: 553-63.
34. Mosser DM, Edwards JP. Exploring the full spectrum of macro-phage activation. Nat Rev Immunol 2008; 8: 958-69.
35. Watt SM, Athanassopoulos A, Harris AL, Tsaknakis G. Human endothelial stem/progenitor cells, angiogenic factors and vascular repair. J R Soc Interface 2010; 7 (Suppl 6): S731-51.
36. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angio-genesis. Science 1997; 275: 964-7.
37. Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: Identity defined? J Cell Mol Med 2009, 13:87-102.
38. Loomans CJ, Wan H, de Crom R, van Haperen R, de Boer HC, Leenen PJ, et al. Angiogenic murine endothelial progenitor cells are derived from a myeloid bone marrow fraction and can be iden-tified by endothelial NO synthase expression. Arterioscler Thromb Vasc Biol 2006; 26: 1760-7.
39. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dim-meler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-6.
40. Romagnani P, Annunziato F, Liotta F, Lazzeri E, Mazzinghi B, Frosali F, et al. CD14+CD34 low cells with stem cell phenotypic and functional features are the major source of circulating endothe-lial progenitors. Circ Res 2005; 97: 314-22.
41. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, et al. Redefining endothelial progenitor cells via clonal analysis and he-matopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-9.
42. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34+AC133+VEGFR-2+ cells are not endo-thelial progenitor cells but distinct, primitive hematopoietic pro-genitors. Exp Hematol 2007; 35: 1109-8.
43. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin In-vest 2000; 105: 71-7.
44. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsi-ble for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
45. Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H, et al. Vascular wall resident progenitor cells: A source for postnatal vasculogenesis. Development 2006; 133: 1543-51.
46. Medina RJ, O'Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, Simpson DA, et al. Molecular analysis of endothelial progeni-tor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics 2010; 3: 18.
47. Medina RJ, O'Neill CL, O'Doherty TM, Knott H, Guduric-Fuchs J, Gardiner TA, et al. Myeloid angiogenic cells act as alternative M2 macrophages and modulate angiogenesis through interleukin-8. Mol Med 2011; 17: 1045-55.
48. Asahara T, Kawamoto A, Masuda H. Concise review: Circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011; 29:1650-5.
49. Stitt AW, O'Neill CL, O'Doherty MT, Archer DB, Gardiner TA, Medina RJ. Vascular stem cells and ischaemic retinopathies. Prog Retin Eye Res 2011; 30: 149-66.
50. Medina RJ, O'Neill CL, Humphreys MW, Gardiner TA, Stitt AW. Outgrowth endothelial cells: Characterisation and their potential for reversing ischaemic retinopathy. Invest Ophthalmol Vis Sci 2010; 51: 5906-13.
51. Medina RJ, O'Neill CL, O'Doherty TM, Wilson SE, Stitt AW. Endothelial progenitors as tools to study vascular disease. Stem Cells Int 2012; 2012: 346735.
52. Isner, J.M., Asahara, T. Pharmaceutical products comprising endo-thelial cell precursors. US6569428 (2003).
53. Asahara, T., Masuda, H. Method for amplification of endothelial progenitor cell in vitro. US20080166327 (2008).
54. Masuda H, Alev C, Akimaru H, Ito R, Shizuno T, Kobori M, et al. Methodological development of a clonogenic assay to determine endothelial progenitor cell potential. Circ Res 2011; 109: 20-37.
55. Costa, M.A., Ishikawa, M., Asahara, T., Masuda, H. Method for amplification and functional enhancement of blood derived pro-genitor cells using a closed culture system. US20120003738 (2012).
56. Hebbel, R.P., Lin, Y., Lollar, J.S. Transgenic circulating endothe-lial cells. US6852537 (2005).
57. Yoder, M.C., Ingram, D.A. Isolation, expansion, and use of clono-genic endothelial progenitor cells. US20050266556 (2005).
58. Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K, et al. Identification of a novel hierarchy of endothelial progeni-tor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-60.
59. Yoder, M.C., Ingram, D.A., Prater, D. Blood vessel formation from endothelial colony forming cells. US20080025956 (2008).
60. Wary, K.K., Zhao, Y., Malik, A.B., Zhao, Y.-Y. Selected endothe-lial progenitor cells and methods for use. US8137968 (2012).
61. Grove, R.I., Smith-Steinhart, C., Hyslop, P.A. Therapeutic use of specialized endothelial progenitor cells. US20120020925 (2012).
62. Popa, E.R., Harmsen, M.C., van der Strate, B.W.A., van Luyn, M.J.A., Hendriks, M. Isolation of endothelial progenitor cell sub-sets and methods for their use. US20060035290 (2006).
63. Laughlin, M.J., Pompili, V. Novel cell populations and uses thereof. US20090047257 (2009).
64. Pecora, A.L., Preti, R.A. Compositions and methods of vascular injury repair. US20120071855 (2012).
65. Huss, R., Raggi, M.C., Stangl, M.J., Nelson, P.C. CD34 stem cell-related methods and compositions. US7998472 (2011).
66. Friedlander, M., Otani, A., Da Silva, K., Moreno, S. Isolated line-age negative hematopoietic stem cells and methods of treatment therewith. US20050129665 (2005).
67. Ritter MR, Banin E, Moreno SK, Aguilar E, Dorrell MI, Friedlander M. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J Clin Invest 2006; 116: 3266-76.
68. Dimmeler, S., Zeiher, A., Koyanagi, M. Mesoangioblast-like cell as well as methods and uses relating thereto. US20100068190 (2010).
69. Koyanagi M, Iwasaki M, Rupp S, Tedesco FS, Yoon CH, Boeckel JN, et al. Sox2 transduction enhances cardiovascular repair capac-ity of blood-derived mesoangioblasts. Circ Res 2010; 106: 1290-302.
70. Yoon, Y.S., Losordo, D.W. Novel multipotent stem cells and use thereof. US20070253937 (2007).
71. Zoldhelyi, P., Willerson, J.T., Liu, Q., Chen, Z.Q. Mesodermal-like cell population for treating ischemia in mammals. US20110104124 (2011).
72. Anversa, P. Compositions of adult organ stem cells and uses thereof. US20110091428 (2011).
73. Anversa, P., Leri, A., Kajstura, J. Compositions comprising vascu-lar and myocyte progenitor cells and methods of their use. US8119123 (2012).
74. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovas-cularization. Faseb J 2006; 20: 1495-7.
75. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-6.
76. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28: 299-307.
77. Losordo, D.W., Bridger, G.J., Isner, J.M. Compositions and meth-ods for treating tissue ischemia. US20060194776 (2006).
78. Scott, E.W., Cogle, C.R. Modulating angiogenesis. US20090291087 (2009).
79. Scott, E.W., Grant, M., May, S. Modulating angiogenesis. US7491389 (2009).
80. Pitchford SC, Furze RC, Jones CP, Wengner AM, Rankin SM. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 2009; 4: 62-72.
81. Rankin, S.M., Pitchford, S.C. Methods. US20110044997 (2011).
82. Bahlmann, F.H., Haller, H. Use of erythropoietin. US20100247451 (2010).
83. Itescu, S. Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue. US8153113 (2012).
84. Son, Y.S., Hong, H.S. Agent for stimulating mobilization of endo-thelial progenitor cells. US20120142596 (2012).
85. Franz, W.M. Remedies for ischemia. US20090297470 (2009).
86. Itescu, S. Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue. US20080057069 (2008).
87. Klaus, S.J., Parobok, I.L., Sirenko, O. Methods for increasing en-dothelial progenitor cells. US20110039885 (2011).
88. Riordan, N.H. Stem cell/endothelial progenitor cell mobilization by nutraceutical formulations. US20110135759 (2011).
89. Zeiher, A., Dimmeler, S., Heeschen, C., Ruetten, H. Use of eNOS transcription enhancers in the cell therapy of ischemic heart dis-eases. US20050101599 (2005).
90. Anversa, P., Leri, A., Kajstura, J. Compositions comprising HDAC inhibitors and methods of their use in restoring stem cell function and preventing heart failure. US20090162329 (2009).
91. Dimmeler, S., Zeiher, A.M., Bonauer, A., Urbich, C. Method for the promotion of angiogenesis, vascularization, or vascular repair or for the inhibition of tumor angiogenesis. US20100324118 (2010).
92. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, et al. MicroRNA-92a controls angiogenesis and func-tional recovery of ischemic tissues in mice. Science 2009; 324: 1710-3.
93. Aikawa, R., Losordo, D.W. Stably transformed bone marrow-derived cells and uses thereof. US20100028312 (2010).
94. van der Strate, B.W.A., Krenning, G., Fernandes, B.C.A., Harmsen, M., van Luyn, M.J.A., Billy, D., Hendriks, M. Endothelial progeni-tor cell compositions and neovascularization. US20100034794 (2010).
95. Kornowski, R., Fuchs, S., Epstein, S.E., Leon, M.B. Conditioned medium of autologous or allogenic progenitor cells for angiogene-sis treatment. US20060057722 (2006).
96. Velazquez, O.C., Gallagher, K.A. Hyperbaric treatment in wound healing. US20100272684 (2010).
97. Herberts CA, Kwa MS, Hermsen HP. Risk factors in the develop-ment of stem cell therapy. J Transl Med 2011; 9: 29.
98. Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Unexpected severe calcification after transplantation of bone mar-row cells in acute myocardial infarction. Circulation 2004; 109: 3154-7.
99. Kikuchi K, Rudolph R, Murakami C, Kowdley K, McDonald GB. Portal vein thrombosis after hematopoietic cell transplantation: Frequency, treatment and outcome. Bone Marrow Transplant 2002; 29: 329-33.
100. Medina RJ, Archer DB, Stitt AW. Eyes open to stem cells: Safety trial may pave the way for cell therapy to treat retinal disease in pa-tients. Stem Cell Res Ther 2011; 2: 47.